First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study

Table 3 Univariate prognostic factor analyses for TPEx progression-free survival

Variable	HR (95%CI)	P value	Median PFS (95%CI)
ECOG(0 vs 1-2)	0.91 (0.30-2.80)	0.87	6.9 mo (5.1-8.8) vs 6.8 mo (4.7-8.9)
Primary tumor site (Hypo/oropharyngeal vs Others)	0.15 (0.02-1.17)	0.04	22 mo (19.9-25.1) vs 6.7 mo (4.7-8.9)
Response (Responders vs Nonresponders)	0.34 (0.12–0.97)	0.04	8.5 mo (5.5-11.5) vs 4.5 mo (2.5-6.5)
Extent of disease at TPEx initiation (Locoregionally advanced vs Metastatic)	0.95 (0.33-2.85)	0.95	6.9 mo (4.2-9.7) vs 6.8 mo (5.6-7.8)
Relapse-free survival of the primary treatment (≤ 24 vs > 24 mo)1	0.37 (0.11-1.21)	0.09	6.1 mo (3.6-8.6) vs 8.5 mo (4.5-12.5)
Previous treatment2(Multimodality vs Unimodality)	0.44 (0.14–1.41)	0.17	7.5 mo (6.3-8.7) vs 6.1 mo (2.7-9.4)
Treatment interruption, discontinuation, or dose reduction (Yes vs No)	1.15 (0.39-3.41)	0.80	6.9 mo (6.4-7.4) vs 6.8 mo (5.0-8.5)
Adverse events (Grade 1-2 vs 3-4)	0.74 (0.23-2.44)	0.62	6.9 mo (5.2-8.6) vs 6.7 mo (0.3-13.9)

¹Time from primary definitive treatment to advanced disease and first-line TPEx initiation.

²Treatment received as primary intention.

Unimodality included surgery or radiotherapy only. Multimodality included surgery and/or radiotherapy +/- chemotherapy. ECOG: Eastern Cooperative Oncology Group; CI: Confidence interval.